Verified

Brittle Bone Disorders Consortium (BBDC) Pilot and Feasibility Grant Program

Autoimmunity, Rasmussen’s, Inflammation & Status Epilepticus Research Network (ARISEN)

The mission of the Brittle Bone Disorders Consortium (BBDC) Pilot and Feasibility Grant Program is to support innovative projects that advance the understanding, diagnosis, management, and treatment of osteogenesis imperfecta (OI) and related heritable skeletal disorders.

The program is intended to foster new research directions, generate preliminary data for future funding applications, and accelerate the development of studies that improve outcomes for individuals affected by brittle bone disorders.

Examples of responsive pilot projects include, but are not limited to:

Analysis of existing BBDC datasets
Genotype-phenotype correlation studies
Natural history and observational studies
Patient-reported outcomes research
Quality-of-life assessments
Studies addressing transition of care across the lifespan
Dental, craniofacial, orthopedic, pulmonary, cardiovascular, or psychosocial manifestations of OI
Biomarker discovery and validation studies
Health services and health equity research
Ancillary studies leveraging existing BBDC protocols and infrastructure
Early-stage interventional clinical studies (with prior NIH and BBDC approval, as applicable)
Other innovative projects aligned with the BBDC mission

Upon completion of funding, investigators are expected to leverage pilot data to support larger grant applications, collaborative studies, and future consortium initiatives. Priority will be given to projects with the potential to improve clinical care, inform future clinical trials, advance scientific understanding, and ultimately enhance the lives of individuals living with brittle bone disorders.

Funds may not be used to support animal research.

Funding Available

Annual funding of up to $15,000 total costs (including indirect costs) is available to support one pilot project for a one-year funding period.

The BBDC intends to fund at least one award during this funding cycle beginning October 15, 2026.

AI Based Application Success Predictor

Predictor	Relevance to grant success
Alignment with ARISEN's disease priorities	Research must address one or more of the consortium's target diseases.
Clinical or translational relevance	Projects should address clinical research gaps rather than animal-only studies.
Scientific significance and innovation	Strong rationale, novel research questions, and potential to advance understanding or treatment.
Methodological rigor and feasibility	A sound study design, realistic timeline, milestones, and achievable objectives.
Patient-oriented impact	Potential to improve diagnosis, treatment, prognosis, or patient outcomes.
Preliminary data and future funding potential	Ability to generate evidence supporting subsequent external funding applications.
Multidisciplinary collaboration	Collaboration across research centers and relevant clinical specialties.
Patient engagement	Meaningful involvement of patients, caregivers, or patient advocacy groups.
Research team and environment	Appropriate investigator expertise, mentoring when required, and access to research resources.
Impact and sustainability	Measurable outcomes and a credible plan for continuing the research beyond the pilot award.

These predictors reflect ARISEN's published research priorities and peer-review criteria; they are not a statistically validated ranking of historical award-winning factors.

arisen.rarediseasesnetwork.org

Grant and organization classification

Category	Details
Organization type	U.S. federally funded research consortium
Funding source	NIH, including NCATS and NICHD
Grant programs	ARISEN Pilot Research Grant; Early-Stage Investigator Pilot Research Grant
Maximum award	Up to $45,000 total costs for the published pilot programs
Project duration	12 months
Historical success rate	Not verified; applicant counts and comparable award data are needed
Official website	ARISEN Funding Opportunities

The 2027 funding announcements list a letter-of-intent deadline of November 13, 2026, with full applications due in February 2027. The pilot grant permits one award, subject to funding approval.

arisen.rarediseasesnetwork.org

Excel-ready entry — Previous Success Predictors: Disease-area alignment; clinical and translational significance; scientific innovation; methodological rigor; preliminary data; patient-oriented research; multidisciplinary collaboration; patient advocacy involvement; investigator expertise; feasibility; measurable outcomes; sustainability; and potential to secure future external funding.

Specialties

Orthopedics

Rare Diseases

Eligibility Requirements

Applicants must:

Hold a doctoral degree (MD, DO, PhD, DDS, DMD, or equivalent)
Be affiliated with a U.S.-based academic, clinical, research, or healthcare institution
Be conducting research relevant to osteogenesis imperfecta or related heritable skeletal disorders

Applications are welcomed from investigators both within and outside the BBDC network.

Early-stage investigators and new investigators are strongly encouraged to apply.

Eligible Countries:

United States

Sponsor Details

Sponsor Institute/Organizations: Autoimmunity, Rasmussen’s, Inflammation & Status Epilepticus Research Network (ARISEN)

Sponsor Type: Corporate/Non-Profit

Address: 3333 Burnet Ave, Cincinnati, OH 45229,

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity